Arkolith/Insider Trading/AVBP/Form 4

OrbiMed Asia GP IV, L.P.

Director, 10% OwnerArriVent Biopharma, Inc. (AVBP) · full profile →Form 4 · filed Jan 31, 2024
Net Buying
Open-Market Buys
$8.0M
Open-Market Sells
$0
Net Open-Market Flow
$8.0M
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2024Buy(P)222K$18.00$4.0M1.5M
Jan 30, 2024Buy(P)222K$18.00$4.0M1.5M
Jan 30, 2024Conversion(C)470K——1.3M
Jan 30, 2024Conversion(C)470K——1.3M
Jan 30, 2024Conversion(C)822K——822K
Jan 30, 2024Conversion(C)822K——822K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2024Conversion(C)822K——0
Jan 30, 2024Conversion(C)822K——0
Jan 30, 2024Conversion(C)470K——0
Jan 30, 2024Conversion(C)470K——0

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-008799) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML